No EMA budget until agency addresses 'failure' on conflicts of interest
This article was originally published in Scrip
The conflicts of interest issue continues to dog the European Medicines Agency after the European Parliament today voted to postpone closing the EMA's 2010 budget.
You may also be interested in...
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.
The pharma and biotech industries have welcomed Australia’s coronavirus recovery budget, which also sets aside funding for research into COVID-19 vaccines and makes positive changes to R&D tax incentives.